(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection ...

A newly posted agenda for next week’s meeting of the just-appointed group of outside vaccine advisers to the US Centers for ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding ...

The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Responding to MAUDE data, some have safety concerns but others aren’t surprised to see more events in higher-risk patients.